KEYWORDS
Educations: Dr. of Biology: Virology. A. Kirhenšteins Institute of Microbiology, Latvian Academy of Sciences, Riga, (Latvian SSR). Scientific Council of Russia, Moscow (USSR), 1988
Ph.D. in Medicine: Cell and Tumour Biology. Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, (Sweden), 2003
Post-doctoral. Cancer epigenetics. Department of Development and Genetics, EBC, Uppsala University, Uppsala (Sweden).
Post-doctoral. RNA technologies in cancer biology. Department of Molecular Medicine and Surgery (MMS), Karolinska Institute, Stockholm,
Qualifications: 2013. – 2019. The scientific expert of the Latvian Council of Science (LZP) in the field of cell biology.
A member of the Scientific Evaluation Committee (SEC) of the 2nd Call for proposals of the European network (7FP) on translational cancer research, ERA-NET TRANSCAN, on the topic “Translational Research on Primary and secondary prevention of cancer”, 2013
Professional experience:
· 09/2008 – present. Leading Scientist at Institute of Microbiology and Virology (IMV), Rīga Stradiņš University (RSU), Riga, Latvia.
· 10/2006 – 08/2008. Researcher, post-doctoral. Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, (Sweden). In the lab of Professor Gunnar Norstedt and Associate Professor Zicai Liang. RNA technologies in cancer biology. RNA-aptamers application for B-cell lymphoma.
· 09/2004-08/2006. Researcher, post-doctoral. Depart of Development and Genetics, Evolutionary Biology Centre (EBC), Uppsala University, Uppsala (Sweden). Under the supervision of Professor Rolf Ohlsson. Cancer epigenetics. Epigenetics of EBV. Regulation of gene expression in normal and cancer cells.
· 07/2003-12/2004. Researcher. Co-supervisor of the project: the cooperation grant between Sweden and Latvia from The Royal Swedish Academy of Sciences. “Involvement of the chemokine receptor genes identified within the human 3p21.3 region, in haematological malignancies and solid tumors”. MTC, Karolinska Institute, Stockholm, (Sweden).
· 03/1997 – 06/2003. Ph.D.-student in Cell and Tumor biology. Microbiology and Tumor Biology Center (MTC), Karolinska Institute, Stockholm, (Sweden). Under the supervision of Professor G. Klein and Associate Professor S. Imreh. “A microcell hybrid based “Elimination Test” to identify chromosome 3 regions that antagonize or favor tumor growth.”
· 06/1994-03/1997. Researcher. Microbiology and Tumor Biology Center (MTC), Karolinska Institute (Stockholm, Sweden). Under the supervision of Prof. G.Klein. Cell and Tumorbiology.
· 03/1992 – 06/1994. Guest-researcher, post-doctoral. Department of Tumor Biology, Karolinska Institute, Stockholm (Sweden). Under the supervision of Prof. G.Klein. Human genome project.
· 04/1987 – 02/1992. Scientist. A.Kirhenšteins Institute of Microbiology, Latvian Academy of Sciences, Riga, (Latvian SSR). In the lab of V.Saulite, MD, Ph.D. Hepatatis B virus. Immunochemistry.
Research Projects:
· 09/2018-08/2021. Project Leader of the Latvian Council of Science (LZP) project Nr. lzp-2018/1-0156 “Investigation of the chemokine receptors CCR1 and CCR2 and EBV infection aimed on disclosure of new markers that can predict the high risk for progression of chronic lymphocytic leukemia.”, IMV, RSU, Riga (Latvia).
· 01/2014-12/2017. Work Package Leader (RSU Work Package) of the Latvian Council of Science (LZP) Cooperation project Nr.651/2014 “Investigation of chemokine receptors CCR1 and CCR2 as potential diagnostic markers of B-cell malignancy progression” (the project coordinator S.Kozireva), A.Kirhenšteins Institute of Microbiology and Virology (AKIMV), Rīga Stradiņš University (RSU), Riga, Latvia.
· 01/2010-12/2012. Coordinator and the Work Package Leader of the ESF (European Social Fund / Government) project in Latvia “Establishment of the new interdisciplinary research group on the development of nanotechnology-based approach in cell biology with applications in medicine” (Nr. 2009/0221/1DP/1.1.1.2.0/09/APIA/VIAA/074). AKIMV, RSU, Riga (Latvia).
· 01/2009-12/2012. Project Leader of the Latvian Council of Science (LZP) project LZP Nr. 09.1392 “The role of the beta-herpesviruses, HHV-6A, HHV-6B, and HHV-7, in the development of high-grade non-Hodgkin’s lymphoma”. AKIMV, RSU, Riga (Latvia).
· 07/2008 – 06/2009. Principal Investigator of the project „Nucleotides-modified RNA-aptamers – the novel strategy for the identification of the molecules that distinguish malignant cell from non-malignant cell: the Burkitt’s lymphoma model” from The Swedish Society of Medicine (Svenska Läkaresällskapet), Stockholm (Sweden), Socialstyrelsen Ref.nr. 2008-21348. Department of Molecular Medicine and Surgery (MMS), Karolinska Institute, Stockholm, (Sweden).
· 07/2006 – 06/2007. Principal Investigator “Epigenetic regulation of the latent EBV genes expression” from The Swedish Society of Medicine (Svenska Läkaresällskapet), Stockholm (Sweden), Socialstyrelsen Ref.nr. 2006-18857. MTC, Karolinska Institute, Stockholm, (Sweden).
Kozireva S, Rudevica Z, Baryshev M, Leonciks A, Kashuba E., Kholodnyuk I. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program. Viruses 2018, 10(5), 239; doi:10.3390/v10050239.
Kholodnyuk I, Rudevica Z, Leonciks A, Ehlin-Henriksson B, Kashuba E. Expression of the chemokine receptors CCR1 and CCR2B is up-regulated in peripheral blood B cells upon EBV infection and in established lymphoblastoid cell lines. Virology, 2017, 512:1-7. PMID: 28892735.
Matveeva A, Kovalevska L, Kholodnyuk I, Ivanivskaya T, Kashuba E. The TGF-beta – SMAD pathway is inactivated in chronic lymphocytic leukemia cells. Experimental Oncology, 2017, 39(4):286-290. PMID: 29284776
Shevchuk Z, Yurchenko MY, Darekar SD, Holodnuka-Kholodnyuk I, Kashuba VI, Kashuba EV. Overexpression of MRPS18-2 in Cancer Cell Lines Results in Appearance of Multinucleated Cells. Acta Naturae, 5(1):85-9, 2013. PMID: 23556133.
Kost-Alimova M, Darai-Ramqvist E, Yau WL, Sandlund A, Fedorova L, Yang Y, Kholodnyuk I, Cheng Y, Li Lung M, Stanbridge E, Klein G, Imreh S. Mandatory chromosomal segment balance in aneuploid tumor cells. BMC Cancer, 26; 7-21, 2007.
Kholodnyuk I., Kozireva S., Kost-Alimova M., Kashuba V., Klein G. and Imreh S. Down regulation of 3p genes, LTF, SLC38A3, and DRR1, upon growth of human chromosome 3–mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer, 119(1), 99-107, 2006.
Yang Y., Jingfeng L., Szeles A., Imreh M.P., Kost-Alimova M., Kiss H., Kholodnyuk I., Fedorova L., Darai E., Klein G. and Imreh S. Consistent downregulation of human lactoferrin gene expressed in A9 murine fibrosarcoma cells, following tumor growth in SCID mice. Cancer Letters, 191, 155-64, 2003.
Kholodnyuk I., Kost-Alimova M., Yang Y., Kiss H., Fedorova L., Klein G. and Imreh S. The Microcell Hybrid Based “Elimination Test” Identifies a 1-Mb Putative Tumor Suppressor Region at 3p22.2-p22.1 Centromeric to the Homozygous Deletion Region Detected in Lung Cancer. Genes Chromosomes & Cancer, 34, 341-344, 2002
Yang Y., Kost-Alimova M., Ingvarsson S., Qianhui Q., Kiss H., Szeles A., Kholodnyuk I., Cuthbert A., Klein G., and Imreh S. Similar regions of human chromosome 3 are eliminated from or retained in human/human and human/mouse microcell hybrids during tumor growth in severe combined immunodeficient (SCID) mice. Proceedings of the national academy of sciences of the United States of America (PNAS), 98, 1136-1141, 2001.
Kholodnyuk I., Szeles A., Yang Y., Klein G. and Imreh S. Inactivation of the Human Fragile Histidine Triad Gene at 3p14.2 in Monochromosomal Human/Mouse Microcell Hybrid-Derived Severe Combined Immunodeficient Mouse Tumors. Cancer Research, 60, (24), 7119-25, 2000.
Kholodnyuk, I. D., Kost-Alimova, M., Kashuba, V. I., Gizatulin, R., Szeles, A., Stanbridge, E. J., Zabarovsky, E. R., Klein, G., and Imreh, S. A 3p21.3 Region is Preferentially Eliminated from Human Chromosome 3/Mouse Microcell Hybrids During Tumor Growth in SCID Mice. Genes Chromosomes & Cancer, 18, 200-211, 1997.
